The CA of JA3 WP4 on “Repetitive transcranial magnetic stimulation for treatment-resistant major depression” is now available.

We are pleased to announce that the CA of JA3 WP4 on “Repetitive transcranial magnetic stimulation for treatment-resistant major depression” is available. The purpose of the assessment is to examine the effectiveness and safety of repetitive transcranial magnetic stimulation (rTMS) in adult patients with treatment-resistant major depression. The analysis included CE-marked rTMS devices. Final version […]

The CA of JA3 WP4 on “Antibacterial-coated Sutures Versus Non-Antibacterial-Coated Sutures for the Prevention of Abdominal, Superficial and Deep Incisional, Surgical Site Infection (SSI)” is now available.

We are pleased to announce that the collaborative rapid assessment of JA3 WP4 on “ANTIBACTERIAL-COATED SUTURES VERSUS NON-ANTIBACTERIAL-COATED SUTURES FOR THE PREVENTION OF ABDOMINAL, SUPERFICIAL AND DEEP INCISIONAL, SURGICAL SITE INFECTION (SSI)” is available. Surgical site infection (SSI) is a frequent type of nosocomial infection, accounting for about 14% to 15% of the total number […]

Screening of Fetal Aneuplodies Whereby Non-invasive Prenatal Test (NIPT)

This is the final project plan of the CA on “Screening of fetal aneuplodies whereby non-invasive prenatal test (NIPT)”. Included are the external comments on the project plan, including the authors’ answers to the comments. Project Plan_OTCA03_external comments Project_Plan_OTCA03_Aneuplodies screening by NIPT_ FINAL

Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib

Final Assessment Report, External Comments/Answers and Project Plan for pharma JA on Regorafenib (Stivarga©) The purpose of the assessment is to evaluate Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Final version of the assessment was published in October 2017. Below […]

Final assessment report on midostaurin (Rydapt©) in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy

Final Assessment Report, External Comments/Answers and Project Plan for pharma JA on midostaurin (Rydapt©) This is the assessment of the relative effectiveness of midostaurin (Rydapt©) in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy for patients in complete response, followed by midostaurin monotherapy for adult patients with newly diagnosed acute myeloid […]

This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our Privacy Policy and our Terms of Use.